梓醇对肝肺综合征大鼠肝肺损伤的保护作用研究

曾子洋; 雷雨豪; 吴宪锋; 宋艾璘; 杨纯勇; 杨智勇; 李雨捷; 易斌

doi:10.16016/j.2097-0927.202312145

您当前的位置：

首页 >

文章列表页 >

梓醇对肝肺综合征大鼠肝肺损伤的保护作用研究

基础医学 | 更新时间：2026-01-09

- 梓醇对肝肺综合征大鼠肝肺损伤的保护作用研究
- Catalpol protects hepatopulmonary syndrome rats against liver and lung injury
- 陆军军医大学学报 2024年46卷第6期页码：587-596
- 作者机构：
  
  1.40038 重庆，陆军军医大学(第三军医大学)第一附属医院麻醉科
  2.400021 重庆，重庆市中医院麻醉科
- 作者简介：
  
  [易斌，E-mail：yibin1974@163.comYI Bin, E-mail: yibin1974@163.com
- 基金信息：
  
  国家自然科学基金(82070630);国家自然科学基金(82100658);重庆市科技局面上项目(cstc2019jcyj-msxmX0667)
- DOI：10.16016/j.2097-0927.202312145
  中图分类号： R282.71;R285.5;R575
- 收稿：2023-12-30，
  
  修回：2024-01-27，
  
  纸质出版：2024-03-30
- 稿件说明：
移动端阅览
曾子洋, 雷雨豪, 吴宪锋, 等. 梓醇对肝肺综合征大鼠肝肺损伤的保护作用研究[J]. 陆军军医大学学报, 2024,46(6):587-596.

Ziyang ZENG, Yuhao LEI, Xianfeng WU, et al. Catalpol protects hepatopulmonary syndrome rats against liver and lung injury[J]. Journal of Army Medical University, 2024, 46(6): 587-596.
曾子洋, 雷雨豪, 吴宪锋, 等. 梓醇对肝肺综合征大鼠肝肺损伤的保护作用研究[J]. 陆军军医大学学报, 2024,46(6):587-596. DOI： 10.16016/j.2097-0927.202312145.

Ziyang ZENG, Yuhao LEI, Xianfeng WU, et al. Catalpol protects hepatopulmonary syndrome rats against liver and lung injury[J]. Journal of Army Medical University, 2024, 46(6): 587-596. DOI： 10.16016/j.2097-0927.202312145.

摘要

目的

探索梓醇通过增强TGR5表达和降低肝胆汁酸水平对胆总管结扎术(CBDL)大鼠肺损伤的保护作用。

方法

将大鼠随机分为三组[Sham组、CBDL组和梓醇(Catalpol)组

]

，评估生存率、动脉血氧分压(PO

)和肺泡-动脉血氧分压差P(A-a)O

、肝功能、肝肺组织病理变化差异；进一步分析胆汁酸表达水平和TGR5的关系以及相关机制。

结果

梓醇治疗改善CBDL导致的肝功能损伤，提高CBDL的生存率和改善了低氧血症；减少了肝、肺血管新生。同时，梓醇通过增强TGR5和降低FXR的表达，减轻BAs水平过高引起肺损伤。

结论

梓醇通过上调TGR5和降低FXR的表达，改善BAs水平过高引起的肺损伤，发挥对CBDL大鼠的肝肺保护作用。

Abstract

Objective

To explore the protective effect of catalpol by enhancing TGR5 expression and reducing bile acid (BAs) level against liver and lung injury in rats with common bile duct ligation (CBDL).

Methods

Fifty male rats were randomly divided into sham-operation group (

=10)

CBDL group (

=20) and catalpol group (

=20). The survival rate

arterial partial pressure of oxygen (PO

) and alveolar and arterial PO

gradient difference [P(A-a)O

]

liver function

and pathological changes in the liver and lungs. The relationship between bile acid level and TGR5 was analyzed.

Results

Catalpol ameliorated liver function damage

improved survival rate and hypoxemia induced by CBDL. It also reduced angiogenesis in the liver and lung. Meanwhile

catalpol mitigated lung injury caused by excessive BAs levels through enhancing TGR5 expression and reducing FXR expression.

Conclusion

The protective effects of catalpol on CBDL lung injury caused by excessive BAs levels through enhancing TGR5 expression and reducing FXR expression.

关键词

Keywords

references

XIAO J, WANG F, WONG N K, et al . Global liver disease burdens and research trends: analysis from a Chinese perspective[J ] . J Hepatol, 2019, 71(1): 212-221. DOI: 10.1016/j.jhep.2019.03.004.

GINÈS P, KRAG A, ABRALDES J G, et al . Liver cirrhosis[J ] . Lancet, 2021, 398(10308): 1359-1376. DOI: 10.1016/S014 0-6736(21)01374-X.

HUANG Y F, LIN C S, CHERNG Y G, et al . A population-based cohort study of mortality of intensive care unit patients with liver cirrhosis[J ] . BMC Gastroenterol, 2020, 20(1): 15. DOI: 10.1186/s12876-020-1163-1.

BENZ F, MOHR R, TACKE F, et al . Pulmonary complications in patients with liver cirrhosis[J ] . J Transl Int Med, 2020, 8(3): 150-158. DOI: 10.2478/jtim-2020-0024.

SURANI S R, MENDEZ Y, ANJUM H, et al . Pulmonary complications of hepatic diseases[J ] . World J Gastroenterol, 2016, 22(26): 6008-6015. DOI: 10.3748/wjg.v22.i26.6008.

RAEVENS S, BORET M, FALLON M B. Hepatopulmonary syndrome[J]. JHEP Rep, 2022, 4(9): 100527. DOI: 10.1016/j.jhepr.2022.100527.

WANG D D, YANG C Y, ZENG Z Y, et al . Extrahepatic angiogenesis: a potential common pathophysiological basis of multiple organ dysfunction in rats with cholestasis cirrhosis[J ] . Front Biosci (Landmark Ed), 2023, 28(10): 272. DOI: 10.31083/j.fbl2810272.

SHENODA B, BOSELLI J. Vascular syndromes in liver cirrhosis[J]. Clin J Gastroenterol, 2019, 12(5): 387-397. DOI: 10.1007/s12328-019-00956-0.

RAEVENS S, GEERTS A, PARIDAENS A, et al . Placental growth factor inhibition targets pulmonary angiogenesis and represents a therapy for hepatopulmonary syndrome in mice[J ] . Hepatology, 2018, 68(2): 634-651. DOI: 10.1002/hep.29579.

YI H M, AN Y L, LV H J, et al . The association of lipopolysaccharide and inflammatory factors with hepatopulmonary syndrome and their changes after orthotopic liver transplantation[J ] . J Thorac Dis, 2014, 6(10): 1469-1475. DOI: 10.3978/j.issn.2072-1439.2014.10.05.

LIU H Y, GU H J, GU L L, et al . CX3CR1 regulates angiogenesis and activation of pro-angiogenic factors and triggers macrophage accumulation in experimental hepatopulmonary syndrome model[J ] . Gastroenterol Hepatol, 2021, 44(2): 115-124. DOI: 10.1016/j.gastrohep.2020.05.021.

ZHANG Y K, WANG C Y, LU J W, et al . Targeting of miR-96-5p by catalpol ameliorates oxidative stress and hepatic steatosis in LDLr-/ -mice via p66shc/cytochrome C cascade[J ] . Aging, 2020, 12(3): 2049-2069. DOI: 10.18632/aging.102721.

YAN J T, WANG C Y, JIN Y, et al . Catalpol ameliorates hepatic insulin resistance in type 2 diabetes through acting on AMPK/NOX4/PI3K/AKT pathway[J ] . Pharmacol Res, 2018, 130: 466-480. DOI: 10.1016/j.phrs.2017.12.026.

CHEN J, YANG Y W, LV Z Y, et al . Study on the inhibitive effect of Catalpol on diabetic nephropathy[J ] . Life Sci, 2020, 257: 118120. DOI: 10.1016/j.lfs.2020.118120.

LIU Z G, ZHU P T, ZHANG L, et al . Autophagy inhibition attenuates the induction of anti-inflammatory effect of catalpol in liver fibrosis[J ] . Biomedecine Pharmacother, 2018, 103: 1262-1271. DOI: 10.1016/j.biopha.2018.04.156.

TIAN X, XIONG Q, CHEN L, et al . Intervention of catalpol on high-fat diet induced nonalcoholic fatty liver disease in mice[J ] . Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2019, 41(6): 746-755. DOI: 10.3881/j.issn.1000-503X.11110.

WU L S, LI H X, CHEN S Y, et al . Catalpol inhibits the proliferation, migration and metastasis of HCC cells by regulating miR-140-5p expression[J ] . Mol Med Rep, 2021, 23(1): 29. DOI: 10.3892/mmr.2020.11667.

ZHAO L N, WANG Y S, LIU Q R. Catalpol inhibits cell proliferation, invasion and migration through regulating miR-22-3p/MTA3 signalling in hepatocellular carcinoma[J]. Exp Mol Pathol, 2019, 109: 51-60. DOI: 10.1016/j.yexmp.2019.104265.

GAO X J, XU J J, LIU H B. Protective effects of catalpol on mitochondria of hepatocytes in cholestatic liver injury[J]. Mol Med Rep, 2020, 22(3): 2424-2432. DOI: 10.3892/mmr.2020.11337.

XIE Z Y, CAO H W, WANG Q, et al . Catalpol inhibits hepatic stellate cell activation by reducing the formation and changing the contents of hepatocyte-derived extracellular vesicles[J ] . J Cell Commun Signal, 2023, 17(3): 723-736. DOI: 10.1007/s12079-022-00716-9.

ZHU P T, WU Y, YANG A H, et al . Catalpol suppressed proliferation, growth and invasion of CT26 colon cancer by inhibiting inflammation and tumor angiogenesis[J ] . Biomed Pharmacother, 2017, 95: 68-76. DOI: 10.1016/j.biopha.2017.08.049.

LIU L, GAO H W, WANG H B, et al . Catalpol promotes cellular apoptosis in human HCT116 colorectal cancer cells via microRNA-200 and the downregulation of PI3K-Akt signaling pathway[J ] . Oncol Lett, 2017, 14(3): 3741-3747. DOI: 10.3892/ol.2 017.6580.

YANG Y, CHEN B, CHEN Y, et al . A comparison of two common bile duct ligation methods to establish hepatopulmonary syndrome animal models[J ] . Lab Anim, 2015, 49(1): 71-79. DOI: 10.1177/0023677214558701.

BEDOSSA P, POYNARD T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group[J]. Hepatology, 1996, 24(2): 289-293. DOI: 10.1002/hep.510240201.

FALLON M B, ABRAMS G A, MCGRATH J W, et al . Common bile duct ligation in the rat: a model of intrapulmonary vasodilatation and hepatopulmonary syndrome[J ] . Am J Physiol, 1997, 272(4 Pt 1): G779-G784. DOI: 10.1152/ajpgi.1997.272.4.G779.

TIAN X, RU Q, XIONG Q, et al . Catalpol attenuates hepatic steatosis by regulating lipid metabolism via AMP-activated protein kinase activation[J ] . Biomed Res Int, 2020, 2020: 6708061. DOI: 10.1155/2020/6708061.

BHATTAMISRA S K, YAP K H, RAO V, et al . Multiple biological effects of an iridoid glucoside, catalpol and its underlying molecular mechanisms[J ] . Biomolecules, 2019, 10(1): 32. DOI: 10.3390/biom10010032.

LI Y J, WU X F, WANG D D, et al . Serum soluble vascular endothelial growth factor receptor 1 as a potential biomarker of hepatopulmonary syndrome[J ] . J Clin Transl Hepatol, 2023, 11(5): 1150-1160. DOI: 10.14218/JCTH.2022.00421.

DE LUCA D, ALONSO A, AUTILIO C. Bile acid-induced lung injury: update of reverse translational biology[J]. Am J Physiol Lung Cell Mol Physiol, 2022, 323(1): L93-L106. DOI: 10.1152/ajplung.00523.2021.

MVNZKER J, HAASE N, TILL A, et al . Functional changes of the gastric bypass microbiota reactivate thermogenic adipose tissue and systemic glucose control via intestinal FXR-TGR5 crosstalk in diet-induced obesity[J ] . Microbiome, 2022, 10(1): 96. DOI: 10.1186/s40168-022-01264-5.

KLINDT C, REICH M, HELLWIG B, et al . The G protein-coupled bile acid receptor TGR5 (Gpbar1) modulates endothelin-1 signaling in liver[J ] . Cells, 2019, 8(11): 1467. DOI: 10.3390/cells8111467.

REICH M, DEUTSCHMANN K, SOMMERFELD A, et al . TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro [J ] . Gut, 2016, 65(3): 487-501. DOI: 10.1136/gutjnl-2015-309458..

DING L L, YANG Q L, ZHANG E Y, et al . Notoginsenoside Ft1 acts as a TGR5 agonist but FXR antagonist to alleviate high fat diet-induced obesity and insulin resistance in mice[J ] . Acta Pharm Sin B, 2021, 11(6): 1541-1554. DOI: 10.1016/j.apsb.2021.03.038.

EL-HANBOSHY S M, HELMY M W, ABD-ALHASEEB M M. Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways[J]. Mol Biol Rep, 2021, 48(11): 7233-7242. DOI: 10.1007/s11033-021-06715-0.

BAKR A G, EL-BAHRAWY A H, TAHA H H, et al . Diosmin enhances the anti-angiogenic activity of sildenafil and pentoxifylline against hepatopulmonary syndrome via regulation of TNF-α/VEGF, IGF-1/PI3K/AKT, and FGF-1/ANG-2 signaling pathways[J ] . Eur J Pharmacol, 2020, 873: 173008. DOI: 10.1016/j.ejphar.2020.173008.

ZHANG J L, LUO B, TANG L P, et al . Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome[J ] . Gastroenterology, 2009, 136(3): 1070-1080. DOI: 10.1053/j.gastro.2008.12.001.

AI Y L, ZHAO Z Y, WANG H Y, et al . Pull the plug: Anti-angiogenesis potential of natural products in gastrointestinal cancer therapy[J ] . Phytother Res, 2022, 36(9): 3371-3393. DOI: 10.1002/ptr.7492.

TSAI C L, CHANGCHIEN C Y, CHEN Y, et al . Survival benefit of statin with anti-angiogenesis efficacy in lung cancer-associated pleural fluid through FXR modulation[J ] . Cancers, 2022, 14(11): 2765. DOI: 10.3390/cancers14112765.

KAWUT S M, KROWKA M J, FORDE K A, et al . Impact of hepatopulmonary syndrome in liver transplantation candidates and the role of angiogenesis[J ] . Eur Respir J, 2022, 60(2): 2102304. DOI: 10.1183/13993003.02304-2021.

MAN S L, LUO C, YAN M Y, et al . Treatment for liver cancer: from sorafenib to natural products[J ] . Eur J Med Chem, 2021, 224: 113690. DOI: 10.1016/j.ejmech.2021.113690.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

梓醇对大鼠慢性脑缺血白质损伤的保护作用